The FDA did not pay heed to evidence while declaring BPA safe for plastics in baby bottles.

An expert panel reviewed  the FDA’s handling of the controversial subject. According to the report of the panelists, the FDA failed to consider studies calling into question the safety of bisphenol A while declaring it safe.

In response to the attack on the claim of the FDA, it quickly issued a statement saying that its view was "based on all available evidence" which indicated that current levels of exposure to BPA through food packaging do not pose an immediate health risk to the public, including infants and babies.

"We need to get that clear -- we did not ignore studies. We looked at all the studies," Norris Alderson, FDA associate commissioner for science, said in a telephone interview.

"The committee gave us valuable guidance on how we can improve our assessment using the current data. But they did not say in any way that I can find that there is an immediate health risk," Alderson said.

But the expert panel found the FDA underestimated the level of BPA babies ingest and  the level of damage it can cause.